AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

5. Chairman’s report (verbal update)

6. Appraisal 1 - Full Submission
   Lipegfilgrastim (Lonquex®) for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)

7. Appraisal 2 - Full Submission
   Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®) for the treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy

8. Appraisal 3 - Limited Submission
   Azithromycin (Zedbac®) for the treatment of community-acquired pneumonia due to susceptible microorganisms in adult patients where initial intravenous therapy is required. Treatment of pelvic inflammatory disease due to susceptible microorganisms in patients where initial intravenous therapy is required. Consideration should be given to official guidance regarding the appropriate use of antibacterial agents

9. Polypharmacy: Guidance for Prescribing in Frail Adults
10. **Appraisal 4 – Full Submission**
   *Fluticasone furoate/vilanterol (as trifenate) (Relvar® Ellipta®)*
   for the regular treatment of asthma in adults and adolescents aged 12 years old and older where use of a combination medicinal product (long-acting beta₂-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta₂-agonists

11. **All Wales Guide: Pharmacotherapy for Smoking Cessation**

12. **Appraisal 5 – Limited Submission**
   *Linagliptin/metformin (Jentadueto®)* for the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control when insulin and metformin alone do not provide adequate glycaemic control

13. **Appraisal 6 - Full Submission**
   *Aripiprazole monohydrate (Abilify Maintena®)* for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole

14. **Report for the Minister of Health and Social Care on the Review of AWMSG’s policy for appraising Orphan and Ultra Orphan Medicines**

**Date of next meeting: Wednesday, 3rd September in Abergavenny**